, but ICER also has an ethical mission, Pearson says. That's because, with limited resources, the US has to provide both affordable care to patients and sustain innovation from private companies, he told Business Insider.this year to recognize the role ICER has played in changing the way we talk about drug prices.
ICER's role and influence will only grow, with even thornier drug price issues coming down the road. A wave of newthat could cure devastating diseases are expected to become available in the next few years, but they will likely involve trade-offs, including cuts for things like state education budgets.
"Not a single one of those pathways is going to be easy. Because it's not like we can suddenly print a whole lot of new money, just because we have anDrugs that cost as much as a house are on the way to treat rare and devastating diseases. The US is scrambling to figure out how to pay for them.The debate about US drug prices sometimes gets simplified down to this: Prices are just too high. But Pearson says it's more nuanced than that.
"Sometimes with drug prices, we're getting a tremendous value. And sometimes patients and the public are getting ripped off," he said."And the problem is we've failed to come up with an approach to distinguish between those two." ICER, based in Boston, aims to help make that distinction. It takes an in-depth look at new drugs for conditions like
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: trtworld - 🏆 101. / 63 Read more »